July 1, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact:	Makoto Kawamura, Senior Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice Regarding Acquisition of Shares in Ishin Pharma Co., Ltd.

TOHO HOLDINGS CO.,LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”) announces that it has decided to acquire shares of Ishin Pharma Co., Ltd. (Headquarters: Tokyo; Representative Director: Akira Usui; hereinafter “Ishin Pharma”), with which it has maintained a capital and business alliance, to make it a subsidiary, as described below.

1. Purpose of Acquisition

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the corporate slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

Ishin Pharma was founded in September 2008 and has been promoting the development of regenerative medical products to provide new treatments for patients suffering from intractable and rare diseases for which no therapeutic methods exist. The company's sheet-form preparation, "AlloStem® Sheet" (generic name: nivadostrocel), obtained manufacturing and marketing approval in April 2026 for the indications, effects, or performances of "dystrophic, junctional, and simplex (limited to severe generalized type) epidermolysis bullosa."

TOHO HOLDINGS is working to establish an essential positioning in domestic pharmaceutical distribution through the handling of specialty products, including regenerative medical products and other products for which future growth is expected. We have decided to make Ishin Pharma a subsidiary based on the judgment that utilizing Ishin Pharma’s product development capabilities in combination with the management resources of the Group will enable us to further strengthen our sales capabilities and enhance our corporate value. As a company that supports the distribution of regenerative medical products, we will strive to ensure the stable delivery of these products to patients suffering from intractable diseases.

2. Overview of Ishin Pharma

(1) Company name:	Ishin Pharma Co., Ltd.
(2) Location:	2-3-11, Nihombashihoncho, Chuo-ku, Tokyo
(3) Representative:	Akira Usui, Representative Director
(4) Established:	September 3, 2008
(5) Business content:	Development, manufacturing and sales of regenerative medical product
(6) Capital:	100 million yen
(7) Fiscal year end:	December 31

3. Schedule

Date of execution of share transfer agreement: From June 14, 2026 onward, sequentially (*)

Effective date: July 6, 2026 (Scheduled)

(*) For certain shareholders, due to procedural requirements, agreements are being executed sequentially from the aforementioned date onward.

4. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS for the current fiscal year and beyond at this time, we believe that it will contribute to increasing the Group's corporate value over the medium to long term. The Company will disclose any impact promptly if a need for timely disclosure arises.